

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
6200577.pn.	2

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L10

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
DATE: Wednesday, May 28, 2003 [Printable Copy](#) [Create Case](#)
Set Name Query
 side by side

Hit Count Set Name
 result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR

<u>L10</u>	6200577.pn.	2	<u>L10</u>
<u>L9</u>	17 and lipid\$	0	<u>L9</u>
<u>L8</u>	L7 and aggregate\$	0	<u>L8</u>
<u>L7</u>	6086902.pn.	2	<u>L7</u>
<u>L6</u>	11 not 15	45	<u>L6</u>
<u>L5</u>	11 same lipid\$	82	<u>L5</u>
<u>L4</u>	aggregate\$ same (nucleic adj acid\$) same vp22	1	<u>L4</u>
<u>L3</u>	L1 and vp22	6	<u>L3</u>
<u>L2</u>	L1 same vp22	1	<u>L2</u>
<u>L1</u>	aggregate\$ same (nucleic adj acid\$) same deliver\$	127	<u>L1</u>

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
l1 not l5	45

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L6

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
DATE: Wednesday, May 28, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR

<u>L6</u>	l1 not l5	45	<u>L6</u>
<u>L5</u>	l1 same lipid\$	82	<u>L5</u>
<u>L4</u>	aggregate\$ same (nucleic adj acid\$) same vp22	1	<u>L4</u>
<u>L3</u>	L1 and vp22	6	<u>L3</u>
<u>L2</u>	L1 same vp22	1	<u>L2</u>
<u>L1</u>	aggregate\$ same (nucleic adj acid\$) same deliver\$	127	<u>L1</u>

END OF SEARCH HISTORY

File 5: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 6:NTIS 1964-2003/May W4

(c) 2003 NTIS, Intl Cpyrght All Rights Res

***File 6: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.**

File 34:SciSearch(R) Cited Ref Sci 1990-2003/May W3

(c) 2003 Inst for Sci Info

***File 34: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.**

File 40:Enviroline(R) 1975-2003/May

File 50:CAB Abstracts 1972-2003/Apr

(c) 2003 CAB International

***File 50: Truncating CC codes is recommended for full retrieval. See Help News50 for details.**

File 65:Inside Conferences 1993-2003/May W4

(c) 2003 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/May W4

(c) 2003 Elsevier Science B.V.

File 73:EMBASE 1974-2003/May W3

(c) 2003 Elsevier Science B.V.

***File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.**

File 94:JICST-EPlus 1985-2003/May W4

(c)2003 Japan Science and Tech Corp(JST)

File 98:General Sci Abs/Full-Text 1984-2003/Apr

(c) 2003 The HW Wilson Co.

File 103:Energy SciTec 1974-2003/May B1

(c) 2003 Contains copyrighted material

***File 103: For access restrictions see Help Restrict.**

File 143:Biol. & Agric. Index 1983-2003/Apr

(c) 2003 The HW Wilson Co

File 144:Pascal 1973-2003/May W3

(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1966-2003/May W3

(c) format only 2003 The Dialog Corp.

***File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.**

File 156:ToxFile 1965-2003/May W3

(c) format only 2003 The Dialog Corporation

***File 156: TOXLINE Special data is now available. See Help News156.**

File 162:Global Health 1983-2003/Apr

(c) 2003 CAB International

***File 162: Effective May 1, name changes from CAB Health to Global Health.**

File 172:EMBASE Alert 2003/May W4

(c) 2003 Elsevier Science B.V.

File 305:Analytical Abstracts 1980-2003/May W1

(c) 2003 Royal Soc Chemistry

***File 305: Alert feature enhanced for multiple files, duplicate removal, customized scheduling. See HELP ALERT.**

File 369:New Scientist 1994-2003/May W2

(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

***File 370: This file is closed (no updates). Use File 47 for more current information.**

File 399:CA SEARCH(R) 1967-2003/UD=13822

(c) 2003 American Chemical Society

***File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.**

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 1998 Inst for Sci Info

File 8: Ei Compendex(R) 1970-2003/May W3

(c) 2003 Elsevier Eng. Info. Inc.

***File 8: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.**

File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Apr
(c) 2003 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2003/May W3
(c) 2003 NewsRx

***File 135: New newsletters are now added. See Help News135 for the complete list of newsletters.**

File 266:FEDRIP 2003/Apr

Comp & dist by NTIS, Intl Copyright All Rights Res

File 315:ChemEng & Biotech Abs 1970-2003/Apr
(c) 2003 DECHEMA

File 357:Derwent Biotech Res. 1982-2003/Jun W1
(c) 2003 Thomson Derwent & ISI

***File 357: File is now current. See HELP NEWS 357.**

Alert feature enhanced for multiple files, etc. See HELP ALERT.

File 358:Current BioTech Abs 1983-2003/Apr
(c) 2003 DECHEMA

File 35:Dissertation Abs Online 1861-2003/Apr
(c) 2003 ProQuest Info&Learning

File 48:SPORTDiscus 1962-2003/May
(c) 2003 Sport Information Resource Centre

File 91:MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential

File 149:TGG Health&Wellness DB(SM) 1976-2003/May W3
(c) 2003 The Gale Group

File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation

***File 159: Cancerlit ceases updating with immediate effect.**

Please see HELP NEWS.

File 164:Allied & Complementary Medicine 1984-2003/May
(c) 2003 BLHCIS

File 442:AMA Journals 1982-2003/Oct B2
(c) 2003 Amer Med Assn -FARS/DARS apply

File 444:New England Journal of Med. 1985-2003/Jun W1
(c) 2003 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

***File 467: For information about updating status please see Help News467.**

Set	Items	Description
---	-----	-----
?s aggregate?	(s)	(nucleic acid)
	397734	AGGREGATE?
	74893	NUCLEIC ACID
S1	0	AGGREGATE? (S) (NUCLEIC ACID)
?s vp22	(s)	aggregate?
	846	VP22
	397734	AGGREGATE?
S2	8	VP22 (S) AGGREGATE?

?rd

...completed examining records

S3 5 RD (unique items)

?show files;ds;t/3,k/all

File 5:Biosis Previews(R) 1969-2003/May W4
(c) 2003 BIOSIS

File 6:NTIS 1964-2003/May W4
(c) 2003 NTIS, Intl Cpyrght All Rights Res

File 34:SciSearch(R) Cited Ref Sci 1990-2003/May W3
(c) 2003 Inst for Sci Info

File 40:Enviroline(R) 1975-2003/May

File 50:CAB Abstracts 1972-2003/Apr
(c) 2003 CAB International

File 65:Inside Conferences 1993-2003/May W4
(c) 2003 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/May W4
(c) 2003 Elsevier Science B.V.

File 73:EMBASE 1974-2003/May W3

(c) 2003 Elsevier Science B.V.

File 94:JICST-EPlus 1985-2003/May W4
(c) 2003 Japan Science and Tech Corp(JST)

File 98:General Sci Abs/Full-Text 1984-2003/Apr
(c) 2003 The HW Wilson Co.

File 103:Energy SciTec 1974-2003/May B1
(c) 2003 Contains copyrighted material

File 143:Biol. & Agric. Index 1983-2003/Apr
(c) 2003 The HW Wilson Co

File 144:Pascal 1973-2003/May W3
(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1966-2003/May W3
(c) format only 2003 The Dialog Corp.

File 156:ToxFile 1965-2003/May W3
(c) format only 2003 The Dialog Corporation

File 162:Global Health 1983-2003/Apr
(c) 2003 CAB International

File 172:EMBASE Alert 2003/May W4
(c) 2003 Elsevier Science B.V.

File 305:Analytical Abstracts 1980-2003/May W1
(c) 2003 Royal Soc Chemistry

File 369:New Scientist 1994-2003/May W2
(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS

File 399:CA SEARCH(R) 1967-2003/UD=13822
(c) 2003 American Chemical Society

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info

File 8:Ei Compendex(R) 1970-2003/May W3
(c) 2003 Elsevier Eng. Info. Inc.

File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Apr
(c) 2003 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2003/May W3
(c) 2003 NewsRx

File 266:FEDRIP 2003/Apr
Comp & dist by NTIS, Intl Copyright All Rights Res

File 315:ChemEng & Biotec Abs 1970-2003/Apr
(c) 2003 DECHEMA

File 357:Derwent Biotech Res. _1982-2003/Jun W1
(c) 2003 Thomson Derwent & ISI

File 358:Current BioTech Abs 1983-2003/Apr
(c) 2003 DECHEMA

File 35:Dissertation Abs Online 1861-2003/Apr
(c) 2003 ProQuest Info&Learning

File 48:SPORTDiscus 1962-2003/May
(c) 2003 Sport Information Resource Centre

File 91:MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential

File 149:TGG Health&Wellness DB(SM) 1976-2003/May W3
(c) 2003 The Gale Group

File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation

File 164:Allied & Complementary Medicine 1984-2003/May
(c) 2003 BLHCIS

File 442:AMA Journals 1982-2003/Oct B2
(c) 2003 Amer Med Assn -FARS/DARS apply

File 444:New England Journal of Med. 1985-2003/Jun W1
(c) 2003 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

Set	Items	Description
S1	0	AGGREGATE? (S) (NUCLEIC ACID)
S2	8	VP22 (S) AGGREGATE?
S3	5	RD (unique items)

>>>KWIC option is not available in file(s): 399

3/3,K/1 (Item 1 from file 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

06956495 BIOSIS NO.: 000089078502

**THREE-DIMENSIONAL STRUCTURES OF MATURABLE AND ABORTIVE CAPSIDS OF EQUINE
HERPESVIRUS 1 FROM CRYOELECTRON MICROSCOPY**

AUTHOR: BAKER T S; NEWCOMB W W; BOOY F P; BROWN J C; STEVEN A C
AUTHOR ADDRESS: LAB. PHYSIOL. BIOL., NATL. INST. ARTHRITIS MUSCULOSKELETAL
SKIN DIS., BUILDING 6, ROOM 114, BETHESDA, MD. 20892.
JOURNAL: J VIROL 64 (2). 1990. 563-573. 1990
FULL JOURNAL NAME: Journal of Virology
CODEN: JOVIA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

...ABSTRACT: which is smeared out in the reconstruction, implying that its distribution is not icosahedrally symmetric or necessarily consistent from particle to particle.sbd.consists of *aggregates* of *VP22* (46 kDa). From several lines of evidence, we conclude that this protein is located entirely within the capsid shell. These *aggregates* may be the remnants of morphogenetic cores retained in capsids interrupted in the process of DNA packaging.

3/3,K/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

136241644 CA: 136(16)241644v PATENT
VP22 protein/nucleic acid aggregates for delivery to cells
INVENTOR(AUTHOR): O'Hare, Peter Francis Joseph; Brewis, Neil Douglas;
Normand, Nadia Michelle; Sunassee, Kavitha Renga
LOCATION: UK,
ASSIGNEE: Phogen Limited
PATENT: PCT International ; WO 200220060 A1 DATE: 20020314
APPLICATION: WO 2001GB4057 (20010910) *GB 200022101 (20000908)
PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-048/00A;
C12N-015/87B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB;
GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU;
SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW
; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

3/3,K/3 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

135087161 CA: 135(7)87161f PATENT
**Uses of transport-active proteins and fusion polypeptides, especially
with VP22 function, for controlling cell cycle and inhibiting cell
proliferation**
INVENTOR(AUTHOR): O'Hare, Peter Francis Joseph; Normand, Nadia Michelle;
Brewis, Neil Douglas; Phelan, Anne
LOCATION: UK,
ASSIGNEE: Phogen Limited
PATENT: PCT International ; WO 200147960 A1 DATE: 20010705
APPLICATION: WO 2000GB4965 (20001221) *GB 9930519 (19991224)
PAGES: 23 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/035A;
A61K-047/48B; A61P-035/00B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU;
AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES;
FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC;

LK; LR; LS; LT; LU; LV; MA; MB; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO;
RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;
MR; NE; SN; TD; TG

3/3,K/4 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0290584 DBR Accession No.: 2002-12431 PATENT

**Use of *aggregates* comprising *VP22* protein/polypeptide with the
transport function of *VP22* and oligonucleotides/polynucleotides with
disaggregating agent, useful for treating or preventing cell
proliferation - vector-mediated gene transfer and expression in host
cell for recombinant protein production and gene therapy**

AUTHOR: O'HARE P F J; BREWIS N D; NORMAND N M; SUNASSEE K R

PATENT ASSIGNEE: PHOGEN LTD 2002

PATENT NUMBER: WO 200220060 PATENT DATE: 20020314 WPI ACCESSION NO.:
2002-304326 (200234)

PRIORITY APPLIC. NO.: GB 200022101 APPLIC. DATE: 20000908

NATIONAL APPLIC. NO.: WO 2001GB4057 APPLIC. DATE: 20010910

LANGUAGE: English

**Use of *aggregates* comprising *VP22* protein/polypeptide with the
transport function of *VP22* and oligonucleotides/polynucleotides with
disaggregating agent, useful for treating or preventing cell
proliferation - vector-mediated gene transfer and expression in host
cell for recombinant protein...**

ABSTRACT: DERWENT ABSTRACT: NOVELTY - Use of *aggregates* comprising *VP22*
protein (or a polypeptide with the transport function of *VP22*), and
oligonucleotides or polynucleotides with a disaggregating agent
(simultaneously or sequentially) to treat target cells by delivering
molecules to the cells and/or preventing cell...

... treating target cells to deliver molecules to the cells and/or prevent
their proliferation and/or kill them comprising: (a) exposing the cells
to the *aggregate* composition cited above; and (b) exposing the cells
to the disaggregating agent cited above, which can promote
disaggregation of the *aggregate* composition in cells, where steps (a)
and (b) are carried out simultaneously or sequentially; (2) a product
comprising the *aggregate* composition and the disaggregating agent, as
combined preparation for administration of these components, either
sequentially or together; (3) a pharmaceutical comprising the
aggregate composition and the disaggregating agent, in combination
with a pharmaceutical excipient; and (4) a cell preparation obtainable
by treating the target cells in vitro as cited in the method above.

BIOTECHNOLOGY - Preferred Composition: The *VP22* protein or the
polypeptide with the transport function of *VP22* is a fusion protein,
which also comprises a non-*VP22* polypeptide sequence. The *VP22*
protein or the polypeptide with the transport function of *VP22* is a
fusion protein is chemically cross linked to a non-*VP22* molecule. The
oligonucleotide or polynucleotide comprises a circular plasmid, and is
linked to an additional molecule. The disaggregating agent is a
photoactivator and can promote disaggregation of the *aggregate*
compositions following illumination with actinic light. Preferably, the
disaggregating agent is a phthalocyanine-containing chromophore. The
disaggregating agent is also an agent that can promote...

...are cells in vitro or in vivo. The method further comprises exposing the
target cells to actinic light after delivery of the disaggregating
agent. The *aggregates* and the disaggregating agent are administered
separately to target cells in vivo at the same loci or at closely
neighboring loci. The *aggregates* and disaggregating agent may also be
administered together as a combined preparation to target cells in

vivo. ACTIVITY - Cytostatic; antipsoriatic; dermatological. Fifty microliters of the *aggregate* solution was directly injected into CT26 tumors in mice, and then the mice were observed for signs of distress.

Twenty four hours after administration of the *aggregates*, the mice were anesthetized and half of the CT26 tumors were illuminated for 10 minutes using a cold light source KL2500 LCD. Twenty four hours after illumination, the tumors were removed from the mice. Controls included mice injected with phosphate buffered saline (PBS), MH3 peptide, or *aggregates* formed using *VP22* having greater than 159-301 protein and intercellular adhesion molecule (ICAM) oligonucleotides instead of the *aggregates* described above. Test *aggregates* were found to induce significant apoptosis of the CT26 tumor cells in comparison to controls following excision of the tumors from the mice. MECHANISM OF ACTION - Gene therapy; protein therapy. USE - The *aggregate* composition and disaggregating agent are useful in the manufacture of a medicament for treating diseases or target cells, and/or preventing cell proliferation and/or...

3/3,K/5 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0260679 DBR Accession No.: 2001-00255 PATENT

***Aggregated* composition suitable for phototherapy or prophylaxis of psoriasis, eczema or skin cancer and for delivering nucleic acids and proteins into cells, comprises transport protein *VP22* and an oligonucleotide - plasmid-mediated gene transfer, expression in Escherichia coli, antisense oligonucleotide, ribozyme and recombinant protein aggregate for cancer therapy**

AUTHOR: O'Hare P F J; Normand N M

CORPORATE SOURCE: Cambridge, UK.

PATENT ASSIGNEE: Phogen 2000

PATENT NUMBER: WO 200053722 PATENT DATE: 20000914 WPI ACCESSION NO.: 2000-594314 (2056)

PRIORITY APPLIC. NO.: GB 9930499 APPLIC. DATE: 19991224

NATIONAL APPLIC. NO.: WO 2000GB897 APPLIC. DATE: 20000310

LANGUAGE: English

***Aggregated* composition suitable for phototherapy or prophylaxis of psoriasis, eczema or skin cancer and for delivering nucleic acids and proteins into cells, comprises transport protein *VP22* and an oligonucleotide**

ABSTRACT: An *aggregated* composition (I) containing a protein having the transport function of a transport protein *VP22*, and an oligonucleotide (antisense or ribozyme) or DNA, is claimed. Also claimed are: making (I) by: mixing a protein with the transport function of *VP22* with the oligonucleotide or DNA; and allowing the obtained mixture to form *aggregates* of 0.1-5 microns; and a cell preparation which has been treated with (I). (I) is useful for preparing a medicament for therapy and for delivering molecules to cells in vitro. The medicament is suitable for phototherapy. The *aggregates* are delivered to target cells such as tumor cells in vivo using e.g. liposome and are useful for treating psoriasis, eczema or skin cancer. In an example, a protein designated 159-301 protein consisting of amino acids 159-301 of the herpes-simplex virus-2 *VP22* protein along with a his6 tag at the C-terminus and a 20-mer phosphorothioate oligonucleotide labeled at the 3'-end with fluorescein was prepared. 159-301 was made in an Escherichia coli expression system expressing a plasmid encoding 159-301 protein. The *aggregates* were then added to HeLa cells and incubated for 12 hr at 37 deg. (28pp)

DESCRIPTORS: plasmid-mediated antisense oligonucleotide, ribozyme, herpes-simplex virus recombinant *VP22* protein *aggregate* gene transfer, expression in Escherichia coli, liposome, fluorescein, appl. psoriasis, eczema, skin cancer gene therapy RNA enzyme herpes virus bacterium lipofection transfection fluorescence tumor DNA...